TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03043469

Intervention type: OTHER
Intervention: six-minute exercise test
Description: Cycling against certain load in a bicycle for 6 minutes. Takes about 16 minutes to be completed together with indirect calorimetry, oxygen saturation monitoring, heart rate variability analysis and continuous monitoring of arterial blood pressure).

Intervention type: OTHER
Intervention: Indirect calorimetry
Description: Breathing through a mask that measures levels of oxygen, carbon dioxide, breathing frequency and others (non-invasively). Takes about 16 minutes to be completed, together with the 6-minute exercise test.

Intervention type: OTHER
Intervention: Indirect calorimetry
Description: Breathing through a mask that measures levels of oxygen, carbon dioxide, breathing frequency and others (non-invasively). Takes about 16 minutes to be completed, together with the 6-minute exercise test.
Study: NCT01505062

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR421869
Description: Formulation: Sterile suspension for intraocular injection, 100 microliters (μL) aliquots in 0.3 milliliter (mL) type I borosilicate glass 'V' vials with a butyl stopper and aluminum crimp seal.~Route of administration: subretinal injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR421869
Description: Formulation: Sterile suspension for intraocular injection, 100 microliters (μL) aliquots in 0.3 milliliter (mL) type I borosilicate glass 'V' vials with a butyl stopper and aluminum crimp seal.~Route of administration: subretinal injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR421869
Description: Formulation: Sterile suspension for intraocular injection, 100 microliters (μL) aliquots in 0.3 milliliter (mL) type I borosilicate glass 'V' vials with a butyl stopper and aluminum crimp seal.~Route of administration: subretinal injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR421869
Description: Formulation: Sterile suspension for intraocular injection, 100 microliters (μL) aliquots in 0.3 milliliter (mL) type I borosilicate glass 'V' vials with a butyl stopper and aluminum crimp seal.~Route of administration: subretinal injection
Study: NCT03043469

Intervention type: OTHER
Intervention: Indirect calorimetry
Description: Breathing through a mask that measures levels of oxygen, carbon dioxide, breathing frequency and others (non-invasively). Takes about 16 minutes to be completed, together with the 6-minute exercise test.

Intervention type: OTHER
Intervention: Indirect calorimetry
Description: Breathing through a mask that measures levels of oxygen, carbon dioxide, breathing frequency and others (non-invasively). Takes about 16 minutes to be completed, together with the 6-minute exercise test.

Intervention type: OTHER
Intervention: Oxygen saturation monitoring
Description: The measurement of the amount of oxygen which is attached to haemoglobin molecules (non-invasively). Takes about 16 minutes to be completed, together with the 6-minute exercise test.
Study: NCT00388739

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intervention: Budesonide
Description: Patients 1-5 years of age who are randomly assigned to the treatment arm will be given a one month supply as well as a prescription (for a 6 month supply) for Pulmicort respules (children with mild persistent disease will receive 0.25 mg bid whereas children with moderate or severe persistent disease will receive 0.5 mg bid).
Study: NCT03043469

Intervention type: OTHER
Intervention: Oxygen saturation monitoring
Description: The measurement of the amount of oxygen which is attached to haemoglobin molecules (non-invasively). Takes about 16 minutes to be completed, together with the 6-minute exercise test.

Intervention type: OTHER
Intervention: Oxygen saturation monitoring
Description: The measurement of the amount of oxygen which is attached to haemoglobin molecules (non-invasively). Takes about 16 minutes to be completed, together with the 6-minute exercise test.
Study: NCT00388739

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Usual care: albuterol + systemic steroids
Description: All children (control and treatment arm) will be given a burst dose of steroids (4 days of prednisone, 1mg/kg/dose to a maximum of 40 mg/dose to be given twice a day) at discharge from the ED. All children 1-5 years of age will also receive standardized discharge medication instructions for using albuterol nebulizer treatments: they will receive a prescription for 2.5mg of albuterol in 3cc Normal Saline for aerosol use via compressor every 3 times a day as a chronic care regimen if they are either in the treatment arm and 1-5 years of age or if they are in the control group and already own a nebulization compressor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Usual care: albuterol + systemic steroids
Description: All children (control and treatment arm) will be given a burst dose of steroids (4 days of prednisone, 1mg/kg/dose to a maximum of 40 mg/dose to be given twice a day) at discharge from the ED. All children 1-5 years of age will also receive standardized discharge medication instructions for using albuterol nebulizer treatments: they will receive a prescription for 2.5mg of albuterol in 3cc Normal Saline for aerosol use via compressor every 3 times a day as a chronic care regimen if they are either in the treatment arm and 1-5 years of age or if they are in the control group and already own a nebulization compressor.
Study: NCT03043469

Intervention type: OTHER
Intervention: Oxygen saturation monitoring
Description: The measurement of the amount of oxygen which is attached to haemoglobin molecules (non-invasively). Takes about 16 minutes to be completed, together with the 6-minute exercise test.
Study: NCT02225886

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ascorbic Acid
Description: 300 mg of intravenous ascorbic acid will be given 3 times a week, postdialysis, in 100 mL saline solution, except for the dialysis sessions when iv iron is administered
Study: NCT03043469

Intervention type: OTHER
Intervention: Heart rate variability analysis
Description: Measurement of the variation in the beat-to-beat interval (non-invasively). Takes about 16 minutes to be completed, together with the 6-minute exercise test.

Intervention type: OTHER
Intervention: Heart rate variability analysis
Description: Measurement of the variation in the beat-to-beat interval (non-invasively). Takes about 16 minutes to be completed, together with the 6-minute exercise test.

Intervention type: OTHER
Intervention: Heart rate variability analysis
Description: Measurement of the variation in the beat-to-beat interval (non-invasively). Takes about 16 minutes to be completed, together with the 6-minute exercise test.
Study: NCT02225886

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ascorbic Acid
Description: 300 mg of intravenous ascorbic acid will be given 3 times a week, postdialysis, in 100 mL saline solution, except for the dialysis sessions when iv iron is administered
Study: NCT00187161

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednison, Vincristine, Cytarabine, Methotrexate, Etoposide, Cyclophosphamide, Doxorubicin
Description: The additional information is contained in the Detailed Description section.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednison, Vincristine, Cytarabine, Methotrexate, Etoposide, Cyclophosphamide, Doxorubicin
Description: The additional information is contained in the Detailed Description section.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednison, Vincristine, Cytarabine, Methotrexate, Etoposide, Cyclophosphamide, Doxorubicin
Description: The additional information is contained in the Detailed Description section.
Study: NCT03043469

Intervention type: OTHER
Intervention: Heart rate variability analysis
Description: Measurement of the variation in the beat-to-beat interval (non-invasively). Takes about 16 minutes to be completed, together with the 6-minute exercise test.

Intervention type: OTHER
Intervention: Continuous measurement of arterial blood pressure
Description: Measurement of blood pressure based on the peripheral pulse using a finger cuff (non-invasively). Takes about 16 minutes to be completed, together with the 6-minute exercise test.

Intervention type: OTHER
Intervention: Continuous measurement of arterial blood pressure
Description: Measurement of blood pressure based on the peripheral pulse using a finger cuff (non-invasively). Takes about 16 minutes to be completed, together with the 6-minute exercise test.

Intervention type: OTHER
Intervention: Continuous measurement of arterial blood pressure
Description: Measurement of blood pressure based on the peripheral pulse using a finger cuff (non-invasively). Takes about 16 minutes to be completed, together with the 6-minute exercise test.
Study: NCT03689738

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Potato (Resistant Starch)
Description: Potato lunch and dinner meals, and an evening snack containing 100 g potatoes and 5 g resistant starch (RS) per meal, providing a total of 300 g/d potatoes, equivalent to roughly two whole potatoes, and 15 g/d RS.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CHO-matched (Low-fiber, RS-free)
Description: Isocaloric, CHO-matched, low-fiber, RS-free lunch and dinner meals, and an evening snack.
Study: NCT02873546

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: transcranial Direct Current Stimulation (tDCS)
Description: After locating the stimulation areas, treatment will be delivered during 30-minute session. Treatment will be occur 2 session per day during 5 consecutive days. Subjects will be monitored during tDCS sessions for any side effects or adverse events.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: transcranial Direct Current Stimulation (tDCS)
Description: After locating the stimulation areas, treatment will be delivered during 30-minute session. Treatment will be occur 2 session per day during 5 consecutive days. Subjects will be monitored during tDCS sessions for any side effects or adverse events.
Study: NCT03920605

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir Disoproxil Fumarate
Description: Patients would receive oral Tenofovir Disoproxil Fumarate 300mg once per day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Peginterferon Alfa-2a
Description: Patients would receive subcutaneous injection of Peginterferon Alfa-2a 180 μg once per week.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Peginterferon Alfa-2a
Description: Patients would receive subcutaneous injection of Peginterferon Alfa-2a 180 μg once per week.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Peginterferon Alfa-2b
Description: Patients would receive subcutaneous injection of Peginterferon Alfa-2b 80 μg once per week.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Peginterferon Alfa-2b
Description: Patients would receive subcutaneous injection of Peginterferon Alfa-2b 80 μg once per week.
Study: NCT01541605

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methylphenidate
Description: tablets for oral use

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: tablets for oral use
Study: NCT00410891

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gatifloxacin
Study: NCT02188446

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational programme for smoking and alcohol cessation
Description: 5 meetings within 6 weeks containing education and pharmacologic support
Study: NCT00934063

Intervention type: DRUG
Intervention: somatropin
Description: For s.c. (under the skin) injection. Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
Study: NCT01352351

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Breastfeeding promotion intervention
Description: * Breastfeeding counseling during monthly microcredit meetings~* Weekly cell phone messages about breastfeeding
Study: NCT00538525

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin, Docetaxel, Cisplatin
Description: Doxorubicin, Docetaxel, Cisplatin
Study: NCT04588532

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAM8-22
Description: Bovine Adrenal Medulla will be applied to 2 previously determined area on the volar forearm (one alone and one in combination with doxepin)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAM8-22
Description: Bovine Adrenal Medulla will be applied to 2 previously determined area on the volar forearm (one alone and one in combination with doxepin)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Histamine
Description: histamine will be applied to 2 previously determined area on the volar forearm (one alone and one in combination with doxepin)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Histamine
Description: histamine will be applied to 2 previously determined area on the volar forearm (one alone and one in combination with doxepin)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cowhage (Mucuna Pruriens)
Description: cowhage spicules will be applied to 2 previously determined area on the volar forearm (one alone and one in combination with doxepin)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cowhage (Mucuna Pruriens)
Description: cowhage spicules will be applied to 2 previously determined area on the volar forearm (one alone and one in combination with doxepin)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxepin
Description: Doxepin cream (antihistamine) will be applied in 4 areas on the volar forearm
Study: NCT02597153

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone HCL Liposome Injection
Study: NCT03868982

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neurally adjusted ventilatory assist
Description: NAVA uses the diaphragm activity to deliver mechanical ventilation
Study: NCT02861378

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phentolamine mesylate
Description: Injection of 1ml at lidocaine injection site

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Water
Description: Injection of 1ml of physiologic saline water at injection site
Study: NCT02196571

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Structured Exercise
Study: NCT00657904

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bicalutamide
Description: 150mg daily
Study: NCT00934063

Intervention type: OTHER
Intervention: No treatment given
Description: Control group not receiving treatment
Study: NCT05446246

Intervention type: PROCEDURE
Intervention: Bariatric surgery
Description: Sleeve gastrectomy

Intervention type: PROCEDURE
Intervention: Bariatric surgery
Description: Sleeve gastrectomy
Study: NCT01690949

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PUR118
Description: inhaled PUR118, BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PUR118
Description: inhaled PUR118, BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PUR118
Description: inhaled PUR118, BID
Study: NCT00591383

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: indibulin
Description: indibulin, dose escalation, 200 mg - 600 mg. Taken twice every day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib
Description: erlotinib taken at 150 mg every morning with food.
Study: NCT02648815

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous catheter drainage
Description: Depending on the operator experience, tandem trocar technique or Seldinger technique can be used. If the Seldinger technique is used, then the catheter tract should be sequentially dilated over a guidewire. Access routes that avoid crossing the bowel and other intervening organs, or major mesenteric, peripancreatic, or retroperitoneal blood vessels are selected to minimize the risk of bacterial contamination and hemorrhage. Successful percutaneous treatment of necrotic collections of the pancreas depends on several important factors. Catheters often need to remain in place for several weeks and sometimes months; hence, close follow-up is required.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Abdominal paracentesis evacuation
Description: Evacuation of peritoneal ascitic fluid using percutaneous catheters
Study: NCT02968394

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: omalizumab
Study: NCT03688113

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tinnitus application
Description: Use of tinnitus application

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Tinnitus application
Description: Use of tinnitus application
Study: NCT02734914

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SF-URS with automatic control of RPP
Description: A new F-URS monitoring and control of RPP using intelligent pressure control device

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: conventional F-URS
Description: Ureteroscopy will be conducted using the ureteral access sheath from Cook Medical to treat renal calculi.
Study: NCT01849003

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-6615
Description: GS-6615 tablet(s) administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-6615
Description: GS-6615 tablet(s) administered orally
Study: NCT01098578

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Floseal
Description: Received 1 syringe of Floseal as treatment for posterior epistaxis.
Study: NCT04180878

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention
Description: Participants received a interactive physical activity monitoring system that allowed study personnel to monitor their activity level.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention 2
Description: Participants received an interactive physical activity monitoring system, an electronic scale to report weekly body weight, weekly hour long conference calls with structured interactive educational lessons led by Health Educator, dietary recalls were completed at three different time points during their participation, and study personnel monitored physical activity levels weekly.
Study: NCT04626531

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Web-Based Education
Description: Participants in the intervention group had unlimited access to the Web site, free of charge. The Web site was designed to run on personal computers and smartphones.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control Group
Description: The control group didn't apply any interference during the study. Participants in the control group continued their routine follow-up.
Study: NCT03372915

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Exposure
Description: Exposure therapy conducted according to standard clinical care practices

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exposure + Inhibitory Learning
Description: Exposure therapy conducted according to practice recommendations based derived from research on inhibitory learning theories of fear extinction
Study: NCT04002427

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous Infusion
Description: 30 µg \[14C\]AZD7594 containing 6.7 kBq (180 nCi) carbon-14 (14C) as a 1 hour infusion.
Study: NCT00503971

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat plus Erlotinib
Description: Phase I:~Dose level 1: 300 mg V d1-7 every 21 days plus 100 mg E daily Dose level 2: 400 mg V d1-7 every 21 days plus 100 mg E daily Dose level 2b: 300 mg V d1-7 and 15-21 every 28 days plus 100 mg E daily Dose level 3: 400 mg V d1-7 and 15-21 every 28 days plus 150 mg E daily~Phase II:~Dose level 3: 400 mg V d1-7 and 15-21 every 28 days plus 150 mg E daily
Study: NCT04002427

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled dose
Description: A single inhalation on one occasion.
Study: NCT01864096

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: One month run-in of 850mg metformin once daily, followed by 850mg twice daily of metformin for 35 months. Total time is 36 months.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One month run-in of placebo tablet once daily, followed by twice daily for 35 months. Total time is 36 months.
Study: NCT04464902

Intervention type: DEVICE
Group type: OTHER
Intervention: brace1
Description: The brace1 can provide resistance when patients want to extend their knee.

Intervention type: DEVICE
Group type: OTHER
Intervention: brace2
Description: The brace1 can't provide resistance when patients want to extend their knee.

Intervention type: OTHER
Group type: OTHER
Intervention: No Intervention
Description: Control Group don't have any brace.
Study: NCT02205359

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: aCRT ON
Description: CRT device with AdaptivCRT enabled (AdaptivBiV and LV)
Study: NCT01914718

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-EPOCH-R
Description: rituximab 375mg/m2 IV day 0, etoposide 50mg/m2/d CIV days 1-4, doxorubicin 10mg/m2/d CIV days 1-4, vincristine 0.4mg/m2/d CIV days 1-4, cyclophosphamide 750mg/m2 IV day 5, prednisone 50mg PO days 1-5 twice per day
Study: NCT02205359

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: aCRT OFF
Description: CRT device with AdaptivCRT disabled
Study: NCT00657904

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: once daily
Study: NCT05387161

Intervention type: OTHER
Intervention: Nutritional intervention
Description: The nutritional intervention will consist in providing general nutritional indications specific for endometriosis and an indicative ungrammatical daily diet plan, which must be followed for the entire period of intervention (6 months).
Study: NCT01607723

Intervention type: OTHER
Group type: OTHER
Intervention: NAVA ventilatory mode
Description: The two ventilatory modes will be studied during 24h in intubated patients in random order.

Intervention type: OTHER
Group type: OTHER
Intervention: PAV+ ventilatory mode
Description: The two ventilatory modes will be studied during 24h in intubated patients in random order.
Study: NCT04396912

Intervention type: PROCEDURE
Intervention: Total thyroidectomy
Description: Patients with thyroid diseases either benign (e.g. multinodular goitre) or malign (e.g. thyroid carcinoma) will be prepared for total thyroidectomy procedure and will be enrolled.
Study: NCT02776267

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Angiolite stent
Description: Following index PCI, patients will be followed via scheduled clinic and/or phone contact at 1-, 3-, 6-, 12- and 24-month. Patient will be randomized to undergo a scheduled repeat coronary angiogram and OCT evaluation at either at 3- or 6-month post index PCI.
Study: NCT04396912

Intervention type: PROCEDURE
Intervention: Total thyroidectomy
Description: Patients with thyroid diseases either benign (e.g. multinodular goitre) or malign (e.g. thyroid carcinoma) will be prepared for total thyroidectomy procedure and will be enrolled.

Intervention type: PROCEDURE
Intervention: Total thyroidectomy
Description: Patients with thyroid diseases either benign (e.g. multinodular goitre) or malign (e.g. thyroid carcinoma) will be prepared for total thyroidectomy procedure and will be enrolled.
Study: NCT04493749

Intervention type: DIAGNOSTIC_TEST
Intervention: ECG measurement
Description: Simultaneous recording of a single-lead ECG signal with the Withings Move ECG and ECG signal for the reference 12-lead ECG